Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

Etiological study of esophageal squamous cell carcinoma in an endemic region: a population-based case control study in Huaian, China

Authors: Zemin Wang, Lili Tang, Guiju Sun, Yuntian Tang, Yin Xie, Shaokang Wang, Xu Hu, Weimin Gao, Stephen B Cox, Jia-Sheng Wang

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

Continuous exposure to various environmental carcinogens and genetic polymorphisms of xenobiotic-metabolizing enzymes (XME) are associated with many types of human cancers, including esophageal squamous cell carcinoma (ESCC). Huaian, China, is one of the endemic regions of ESCC, but fewer studies have been done in characterizing the risk factors of ESCC in this area. The aims of this study is to evaluate the etiological roles of demographic parameters, environmental and food-borne carcinogens exposure, and XME polymorphisms in formation of ESCC, and to investigate possible gene-gene and gene-environment interactions associated with ESCC in Huaian, China.

Methods

A population based case-control study was conducted in 107 ESCC newly diagnosed cases and 107 residency- age-, and sex-matched controls in 5 townships of Huaian. In addition to regular epidemiological and food frequency questionnaire analyses, genetic polymorphisms of phase I enzymes CYP1A1, CYP1B1, CYP2A6, and CYP2E1, and phase II enzymes GSTM1, GSTT1, GSTP1, and microsomal epoxide hydrolase (EPHX) were assessed from genomic DNA using PCR based techniques.

Results

Consuming acrid food, fatty meat, moldy food, salted and pickled vegetables, eating fast, introverted personality, passive smoking, a family history of cancer, esophageal lesion, and infection with Helicobacter pylori were significant risk factors for ESCC (P < 0.05). Regular clean up of food storage utensils, green tea consumption, and alcohol abstinence were protective factors for ESCC (P < 0.01). The frequency of the GSTT1 null genotype was higher in cases (59.4%) compared to controls (47.2%) with an odds ratio (OR) of 1.68 and 95% confidence interval (CI) from 0.96 to 2.97 (P = 0.07), especially in males (OR = 2.78; 95% CI = 1.22–6.25; P = 0.01). No associations were found between polymorphisms of CYP1A1, CYP1B1, CYP2A6, CYP2E1, GSTM1, GSTP1, and EPHX and ESCC (P > 0.05).

Conclusion

Our results demonstrated that dietary and environmental exposures, some demographic parameters and genetic polymorphism of GSTT1 may play important roles in the development of ESCC in Huaian area, China.
Appendix
Available only for authorised users
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55 (2): 74-108.CrossRefPubMed
2.
Parkin DM, Laara E, Muir CS: Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer. 1988, 41 (2): 184-197.CrossRefPubMed
3.
Yang L, Parkin DM, Li L, Chen Y: Time trends in cancer mortality in China: 1987-1999. Int J Cancer. 2003, 106 (5): 771-783. 10.1002/ijc.11300.CrossRefPubMed
4.
Bai SX, Zhang S, Li BQ: Primary esophageal adenocarcinoma. Chin J Oncol. 1989, 11: 383-385.
5.
Lu SH, Chui SX, Yang WX, Hu XN, Guo LP, Li FM: Relevance of N-nitrosamines to oesophageal cancer in China. IARC Sci Publ. 1991, 11-17.
6.
Ribeiro U, Posner MC, Safatle-Ribeiro AV, Reynolds JC: Risk factors for squamous cell carcinoma of the oesophagus. Br J Surg. 1996, 83 (9): 1174-1185. 10.1046/j.1365-2168.1996.02421.x.CrossRefPubMed
7.
Stoner GD, Gupta A: Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis. 2001, 22 (11): 1737-1746. 10.1093/carcin/22.11.1737.CrossRefPubMed
8.
Yang CS: Research on esophageal cancer in China: a review. Cancer Res. 1980, 40 (8 Pt 1): 2633-2644.PubMed
9.
Lin K, Shen W, Shen Z, Wu Y, Lu S: Dietary exposure and urinary excretion of total N-nitroso compounds, nitrosamino acids and volatile nitrosamine in inhabitants of high- and low-risk areas for esophageal cancer in southern China. Int J Cancer. 2002, 102 (3): 207-211. 10.1002/ijc.10698.CrossRefPubMed
10.
Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey SM, Dong ZW, Mark SD, Qiao YL, Taylor PR: Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2005, 113 (3): 456-463. 10.1002/ijc.20616.CrossRefPubMed
11.
Yang CS, Sun Y, Yang QU, Miller KW, Li GY, Zheng SF, Ershow AG, Blot WJ, Li JY: Vitamin A and other deficiencies in Linxian, a high esophageal cancer incidence area in northern China. J Natl Cancer Inst. 1984, 73 (6): 1449-1453.PubMed
12.
Vineis P: Individual susceptibility to carcinogens. Oncogene. 2004, 23 (38): 6477-6483. 10.1038/sj.onc.1207897.CrossRefPubMed
13.
Lu XM, Zhang YM, Lin RY, Arzi G, Wang X, Zhang YL, Zhang Y, Wang Y, Wen H: Relationship between genetic polymorphisms of metabolizing enzymes CYP2E1, GSTM1 and Kazakh's esophageal squamous cell cancer in Xinjiang, China. World J Gastroenterol. 2005, 11 (24): 3651-3654.CrossRefPubMedPubMedCentral
14.
Ingelman-Sundberg M: Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol. 2004, 369 (1): 89-104. 10.1007/s00210-003-0819-z.CrossRefPubMed
15.
Autrup H: Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. Mutat Res. 2000, 464 (1): 65-76.CrossRefPubMed
16.
Vogl FD, Taioli E, Maugard C, Zheng W, Pinto LF, Ambrosone C, Parl FF, Nedelcheva-Kristensen V, Rebbeck TR, Brennan P, Boffetta P: Glutathione S-transferases M1, T1, and P1 and breast cancer: a pooled analysis. Cancer Epidemiol Biomarkers Prev. 2004, 13 (9): 1473-1479.PubMed
17.
Zielinska E, Zubowska M, Bodalski J: Polymorphism within the glutathione S-transferase P1 gene is associated with increased susceptibility to childhood malignant diseases. Pediatr Blood Cancer. 2004, 43 (5): 552-559. 10.1002/pbc.20059.CrossRefPubMed
18.
Casson AG, Zheng Z, Chiasson D, MacDonald K, Riddell DC, Guernsey JR, Guernsey DL, McLaughlin J: Associations between genetic polymorphisms of Phase I and II metabolizing enzymes, p53 and susceptibility to esophageal adenocarcinoma. Cancer Detect Prev. 2003, 27 (2): 139-146. 10.1016/S0361-090X(03)00033-3.CrossRefPubMed
19.
Zhang JH, Jin X, Li Y, Wang R, Guo W, Wang N, Wen DG, Chen ZF, Kuang G, Wei LZ, Wang SJ: Epoxide hydrolase Tyr113His polymorphism is not associated with susceptibility to esophageal squamous cell carcinoma in population of North China. World J Gastroenterol. 2003, 9 (12): 2654-2657.CrossRefPubMedPubMedCentral
20.
Oude Ophuis MB, Manni JJ, Peters WH: Glutathione S-transferase T1 null polymorphism and the risk for head and neck cancer. Acta Otolaryngol. 2006, 126 (3): 311-317. 10.1080/00016480500416355.CrossRefPubMed
21.
Gao CM, Takezaki T, Wu JZ, Li ZY, Liu YT, Li SP, Ding JH, Su P, Hu X, Xu TL, Sugimura H, Tajima K: Glutathione-S-transferases M1 (GSTM1) and GSTT1 genotype, smoking, consumption of alcohol and tea and risk of esophageal and stomach cancers: a case-control study of a high-incidence area in Jiangsu Province, China. Cancer Lett. 2002, 188 (1-2): 95-102. 10.1016/S0304-3835(02)00115-5.CrossRefPubMed
22.
Tan W, Song N, Wang GQ, Liu Q, Tang HJ, Kadlubar FF, Lin DX: Impact of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferases M1, T1, and P1 on susceptibility to esophageal cancer among high-risk individuals in China. Cancer Epidemiol Biomarkers Prev. 2000, 9 (6): 551-556.PubMed
23.
Wang LD, Zheng S, Liu B, Zhou JX, Li YJ, Li JX: CYP1A1, GSTs and mEH polymorphisms and susceptibility to esophageal carcinoma: study of population from a high- incidence area in north China. World J Gastroenterol. 2003, 9 (7): 1394-1397.CrossRefPubMedPubMedCentral
24.
Xing D, Tan W, Lin D: Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population (review). Oncol Rep. 2003, 10 (5): 1615-1623.PubMed
25.
Hong YS, Chang JH, Kwon OJ, Ham YA, Choi JH: Polymorphism of the CYP1A1 and glutathione-S-transferase gene in Korean lung cancer patients. Exp Mol Med. 1998, 30 (4): 192-198.CrossRefPubMed
26.
Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR: Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis. 1997, 18 (4): 641-644. 10.1093/carcin/18.4.641.CrossRefPubMed
27.
London SJ, Yuan JM, Coetzee GA, Gao YT, Ross RK, Yu MC: CYP1A1 I462V genetic polymorphism and lung cancer risk in a cohort of men in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 2000, 9 (9): 987-991.PubMed
28.
Saintot M, Malaveille C, Hautefeuille A, Gerber M: Interaction between genetic polymorphism of cytochrome P450-1B1 and environmental pollutants in breast cancer risk. Eur J Cancer Prev. 2004, 13 (1): 83-86. 10.1097/00008469-200402000-00013.CrossRefPubMed
29.
de Jong DJ, van der Logt EM, van Schaik A, Roelofs HM, Peters WH, Naber TH: Genetic polymorphisms in biotransformation enzymes in Crohn's disease: association with microsomal epoxide hydrolase. Gut. 2003, 52 (4): 547-551. 10.1136/gut.52.4.547.CrossRefPubMedPubMedCentral
30.
Tan W, Chen GF, Xing DY, Song CY, Kadlubar FF, Lin DX: Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int J Cancer. 2001, 95 (2): 96-101. 10.1002/1097-0215(20010320)95:2<96::AID-IJC1017>3.0.CO;2-2.CrossRefPubMed
31.
Li K, Yu P: Food groups and risk of esophageal cancer in Chaoshan region of China: a high-risk area of esophageal cancer. Cancer Invest. 2003, 21 (2): 237-240. 10.1081/CNV-120016420.CrossRefPubMed
32.
Ke L, Ping Y, Ge H: Protective action of fresh fruit and vegetable consumption on the synergic effect of alcohol and tobacco use on esophageal cancer in South China. Nutrition. 2003, 19 (9): 821-10.1016/S0899-9007(03)00146-1.CrossRefPubMed
33.
De Stefani E, Deneo-Pellegrini H, Ronco AL, Boffetta P, Brennan P, Munoz N, Castellsague X, Correa P, Mendilaharsu M: Food groups and risk of squamous cell carcinoma of the oesophagus: a case-control study in Uruguay. Br J Cancer. 2003, 89 (7): 1209-1214. 10.1038/sj.bjc.6601239.CrossRefPubMedPubMedCentral
34.
Shen H, Xu Y, Shen J: Etiological relationship between pickled vegetables and esophageal cancer in Huai'an epidemic area. Acta academiae medicinae nanjing. 1997, 17 (2): 119-122.
35.
Gao CM, Takezaki T, Ding JH, Li MS, Tajima K: Protective effect of allium vegetables against both esophageal and stomach cancer: a simultaneous case-referent study of a high-epidemic area in Jiangsu Province, China. Jpn J Cancer Res. 1999, 90 (6): 614-621.CrossRefPubMed
36.
Pickled vegetables. IARC Monogr Eval Carcinog Risks Hum. 1993, 56: 83-113.
37.
Abnet CC, Borkowf CB, Qiao YL, Albert PS, Wang E, Merrill AH, Mark SD, Dong ZW, Taylor PR, Dawsey SM: Sphingolipids as biomarkers of fumonisin exposure and risk of esophageal squamous cell carcinoma in china. Cancer Causes Control. 2001, 12 (9): 821-828. 10.1023/A:1012228000014.CrossRefPubMed
38.
Mandard AM, Hainaut P, Hollstein M: Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res. 2000, 462 (2-3): 335-342.CrossRefPubMed
39.
Johnson KC: Accumulating evidence on passive and active smoking and breast cancer risk. Int J Cancer. 2005, 117 (4): 619-628. 10.1002/ijc.21150.CrossRefPubMed
40.
Centers for Disease Control and Prevention (CDC): 1986 Surgeon General's report: the health consequences of involuntary smoking. MMWR Morb Mortal Wkly Rep. 1986, 35 (50): 769-770.
41.
Agency USEP: Respiratory health effects of passive smoking: lung cancer and other disorders. Office of Health and Environmental Assessment, Office of Research and Development, Washington, DC. 1992, EPA/600/6-90/006F.
42.
International Agency for Research on Cancer: Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. 2004, 83: 1-1438.
43.
Castelli E, Hrelia P, Maffei F, Fimognari C, Foschi FG, Caputo F, Cantelli-Forti G, Stefanini GF, Gasbarrini G: Indicators of genetic damage in alcoholics: reversibility after alcohol abstinence. Hepatogastroenterology. 1999, 46 (27): 1664-1668.PubMed
44.
Wu M, Zhao JK, Hu XS, Wang PH, Qin Y, Lu YC, Yang J, Liu AM, Wu DL, Zhang ZF, Frans KJ, van 't Veer P: Association of smoking, alcohol drinking and dietary factors with esophageal cancer in high- and low-risk areas of Jiangsu Province, China. World J Gastroenterol. 2006, 12 (11): 1686-1693.CrossRefPubMedPubMedCentral
45.
Sakata K, Hoshiyama Y, Morioka S, Hashimoto T, Takeshita T, Tamakoshi A: Smoking, alcohol drinking and esophageal cancer: findings from the JACC Study. J Epidemiol. 2005, 15 Suppl 2: S212-9. 10.2188/jea.15.S212.CrossRefPubMed
46.
Yang CX, Wang HY, Wang ZM, Du HZ, Tao DM, Mu XY, Chen HG, Lei Y, Matsuo K, Tajima K: Risk factors for esophageal cancer: a case-control study in South-western China. Asian Pac J Cancer Prev. 2005, 6 (1): 48-53.PubMed
47.
de Martel C, Llosa AE, Farr SM, Friedman GD, Vogelman JH, Orentreich N, Corley DA, Parsonnet J: Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma. J Infect Dis. 2005, 191 (5): 761-767. 10.1086/427659.CrossRefPubMed
48.
Henrik Siman J, Forsgren A, Berglund G, Floren CH: Helicobacter pylori infection is associated with a decreased risk of developing oesophageal neoplasms. Helicobacter. 2001, 6 (4): 310-316. 10.1046/j.1523-5378.2001.00041.x.CrossRefPubMed
49.
Wu DC, Wu IC, Lee JM, Hsu HK, Kao EL, Chou SH, Wu MT: Helicobacter pylori infection: a protective factor for esophageal squamous cell carcinoma in a Taiwanese population. Am J Gastroenterol. 2005, 100 (3): 588-593. 10.1111/j.1572-0241.2005.40623.x.CrossRefPubMed
50.
Gao YT, McLaughlin JK, Blot WJ, Ji BT, Dai Q, Fraumeni JF: Reduced risk of esophageal cancer associated with green tea consumption. J Natl Cancer Inst. 1994, 86 (11): 855-858.CrossRefPubMed
51.
Fujiki H: Green tea: Health benefits as cancer preventive for humans. Chem Rec. 2005, 5 (3): 119-132. 10.1002/tcr.20039.CrossRefPubMed
52.
de Boer JG, Yang H, Holcroft J, Skov K: Chemoprotection against N-nitrosomethylbenzylamine-induced mutation in the rat esophagus. Nutr Cancer. 2004, 50 (2): 168-173. 10.1207/s15327914nc5002_6.CrossRefPubMed
53.
Sun CL, Yuan JM, Lee MJ, Yang CS, Gao YT, Ross RK, Yu MC: Urinary tea polyphenols in relation to gastric and esophageal cancers: a prospective study of men in Shanghai, China. Carcinogenesis. 2002, 23 (9): 1497-1503. 10.1093/carcin/23.9.1497.CrossRefPubMed
54.
Hou Z, Sang S, You H, Lee MJ, Hong J, Chin KV, Yang CS: Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Cancer Res. 2005, 65 (17): 8049-8056.PubMed
55.
Lin DX, Tang YM, Peng Q, Lu SX, Ambrosone CB, Kadlubar FF: Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1. Cancer Epidemiol Biomarkers Prev. 1998, 7 (11): 1013-1018.PubMed
56.
Wang AH, Sun CS, Li LS, Huang JY, Chen QS, Xu DZ: Genetic susceptibility and environmental factors of esophageal cancer in Xi'an. World J Gastroenterol. 2004, 10 (7): 940-944.PubMedPubMedCentral
57.
Stephens EA, Taylor JA, Kaplan N, Yang CH, Hsieh LL, Lucier GW, Bell DA: Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics. 1994, 4 (4): 185-192. 10.1097/00008571-199408000-00002.CrossRefPubMed
58.
Gao C, Takezaki T, Wu J, Li Z, Wang J, Ding J, Liu Y, Hu X, Xu T, Tajima K, Sugimura H: Interaction between cytochrome P-450 2E1 polymorphisms and environmental factors with risk of esophageal and stomach cancers in Chinese. Cancer Epidemiol Biomarkers Prev. 2002, 11 (1): 29-34.CrossRefPubMed
Metadata
Title
Etiological study of esophageal squamous cell carcinoma in an endemic region: a population-based case control study in Huaian, China
Authors
Zemin Wang
Lili Tang
Guiju Sun
Yuntian Tang
Yin Xie
Shaokang Wang
Xu Hu
Weimin Gao
Stephen B Cox
Jia-Sheng Wang
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-287

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue

Technical advance

A novel approach for rapid screening of mitochondrial D310 polymorphism

Research article

The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis

Research article

Over-representation of specific regions of chromosome 22 in cells from human glioma correlate with resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea

Research article

KIAA0101 (OEACT-1), an expressionally down-regulated and growth-inhibitory gene in human hepatocellular carcinoma

Research article

SNP-SNP interactions in breast cancer susceptibility

Research article

Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits